Phase II Study of Pemetrexed+Bevacizumab for previously untreated elderly patients with nonsquamous non-small-cell lung cancer
- Conditions
- onsquamous non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000008781
- Lead Sponsor
- Toho university medical center sakura hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Not provided
1) History of active double cancer within 5 years. 2) Severe infection 3) History of hemoptysis with 2.5mL or more. 4) Continued bloody phlegm. 5) Received anticoagulant drug(including Aspirin over 325mg/day) within the past 10 days. 6) Perforation of the digestive tract or history of the perforation of the digestive tract within the past one year. 7) Severe comorbidity (heart failure Tendency to hemorrhages uncontrollable hypertension, uncontrollable diabetes, etc) 8) Arterial thromboembolism and Venous thromboembolism within the past one year. 9)Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 10) Planning of surgery or thoracic radiotherapy during the trial. 11) Major surgical procedure 12)With a history of drug sensitivity. 13)Pregnant or lactating women or those who declined contraception. 14) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Overall survival Response rate Time to responce Safety Qo